No Data
Treating IgA nephropathy! Novartis (NVS.US) intends to include avacopan in priority review.
According to the official website of CDE, Norvatis (NVS.US) hydrochloride afoxitant tablets are planned to be included in priority review.
Novartis (NVS.US) has had its application for Lutetium [177Lu] oxodotreotide accepted by the Center for Drug Evaluation (CDE) for market approval.
Nuclear medicine, represented by radiopharmaceutical therapy, is an area where Novartis has heavily invested.
Schrödinger Scores Big Despite Q3 Miss As Novartis Collaboration Promises Billions In Milestones: Details
Schrodinger Shares Are Trading Higher After the Company Raised Its FY24 Software Revenue Growth Guidance. Additioanlly, the Company Announced a Research Collaboration and License Agreement With Novartis to Advance Multiple Development Candidates.
Schrödinger's Stock Pops as It Enters Collaboration Pact With Novartis Worth up to $2.5 Billion
Schrödinger Announced Research Collaboration And License Agreement With Novartis To Advance Multiple Development Candidates Into Novartis's Portfolio For Further Development, Schrödinger To Receive $150M Upfront And Eligible To Receive Up To...
No Data
No Data
